Validated eTMF system with role-based permissions.
A validated eTMF system with role-based permissions lets an administrator assign each user — sponsor staff, CRO monitors, investigator site coordinators, auditors — a specific level of access (view-only, edit, approve, admin) tied to their role, rather than an all-or-nothing login. Combined with a documented, tested access-control setup (the "validated" part), this satisfies 21 CFR 11.10(d)'s requirement to limit system access to authorized individuals while keeping an unbroken audit trail of who saw or changed what.
In an electronic Trial Master File, role-based access control (RBAC) means every user's permissions are determined by the role they're assigned — not configured one person at a time. A study coordinator, a regulatory affairs lead, a CRO monitor, and an outside auditor all need to work inside the same TMF, but none of them should have the same view of it.
A mature RBAC model in an eTMF typically separates permissions along a few dimensions:
Full edit/upload rights, review-and-approve rights, or read-only viewing — often with a further split between seeing final, approved documents only versus seeing drafts and in-progress work.
Access can be scoped to an entire TMF, to a specific study, to a specific zone of the TMF Reference Model (Regulatory, Safety Reporting, Site Management, and so on), or even to an individual document.
Internal staff typically hold standing, full-platform access; external parties — a CRO, an inspector, an auditor — often need time-boxed or license-limited access that can be granted in minutes and revoked just as fast once their engagement ends.
The word "validated" matters as much as "role-based." A permission model is only as trustworthy as the evidence that it works as configured — that a read-only user genuinely cannot edit a document, that role changes are logged, and that the software itself has been tested against its own access-control requirements as part of the vendor's validation package.
This isn't a nice-to-have. 21 CFR 11.10(d) directly requires that systems used to create, modify, maintain, or transmit electronic records "limit system access to authorized individuals" [1]. The FDA's October 2024 guidance on electronic systems, records, and signatures in clinical investigations spells out what that looks like in practice: "logical and physical access controls should be integral to electronic systems used in clinical investigations to limit system access to authorized users," each person should "work only under their own usernames and passwords... and should not share login information with others," and sponsors should maintain "a record of all clinical trial personnel who are authorized to access the electronic system as well as a description of their access privileges" [2]. The same guidance calls out that the ability to change a system's date or time should itself be restricted to administrators, with any change documented.
ICH E6(R3) — the internationally harmonized Good Clinical Practice guideline, which the FDA formally adopted in September 2025 — extends the same expectation into its computerized systems requirements, treating access controls and defined user roles as a baseline element of any system used to manage trial data or documents, not an optional hardening step [3].
The reason both bodies keep circling back to access control is simple: an audit trail is only meaningful if you can trust who generated each entry in it. If ten people share one login, "who approved this document" stops being an answerable question — which is precisely the kind of gap inspectors look for. Kivo's own 21 CFR Part 11 Compliance Checklist covers this alongside the rest of what Part 11 requires of an electronic records system.
Not every system that claims "role-based access" implements it the same way. A handful of capabilities separate a permission model that will hold up under inspection from one that looks fine in a sales demo:
Beyond a generic "admin vs. user" split — the ability to define roles that match how your organization actually works, including read-only, review-only, and upload-only variants. Granularity matters most at the boundary between zones of the TMF Reference Model: a CRA monitoring a single site typically needs edit rights in Site Management and Investigational Product but should have no reason to touch Regulatory correspondence or Safety Reporting for the same study. A system that can only turn access on or off for an entire TMF forces you to either over-grant (give the CRA full-study access because scoping it down isn't possible) or under-grant (deny access to something they legitimately need because the roles aren't fine-grained enough). Look for roles that can be composed — access level plus scope plus duration configured independently — rather than a fixed list of five or six pre-built roles that don't map cleanly onto how your team actually splits responsibility.
A CRO monitor or inspector should be grantable access in minutes for the duration of their engagement, not added as a full standing user and manually remembered for offboarding. In practice this means the system supports pre-configured role templates for common external-party types (monitor, auditor, inspector, site coordinator) so an administrator isn't reconstructing a permission set from scratch every time a new external party needs access. De-provisioning deserves just as much scrutiny as provisioning: a genuinely common inspection finding is a former CRO employee or a site coordinator who left a study months earlier but still has an active, unreviewed login. A system that supports time-boxed access — automatically expiring at a defined date rather than requiring someone to remember to revoke it — closes that gap without relying on an administrator's memory.
Every access event and every permission change should itself be logged, automatically and without the option to disable logging — not just who edited a document, but who granted, modified, or revoked someone else's access, and when. This should be available as its own reviewable report, distinct from a general activity log buried among thousands of document-level entries. That distinction matters for periodic access review: most quality systems expect a recurring reconciliation of who currently has access to what, checked against who should still have it, and a system that can produce a clean current-access report on demand makes that a query rather than a manual audit.
Date/time changes, user-role assignment, and configuration changes should be restricted to a named administrator role, per the FDA's October 2024 guidance above. Worth asking further: can the same administrator role also approve or sign off on trial documents, or is user administration itself separated from content approval? Combining the two in one role means the person who controls access is also the person whose work that access controls — a segregation-of-duties gap that's easy to overlook until an inspector asks who can both grant themselves broader access and use it unreviewed.
SSO reduces password-sharing risk at the source by eliminating a separate system password to begin with, and automatic session timeouts limit the exposure window if a device is left unattended. The FDA's October 2024 guidance frames access-control method selection as risk-based, calling out multifactor authentication and biometrics as options alongside strong login credentials — the point isn't that every system needs every mechanism, but that the choice should be a documented, deliberate one rather than whatever the vendor happened to ship by default.
It's not enough for a vendor to say permissions work as described — ask whether access control is explicitly covered in the system's own validation testing (IQ/OQ/PQ or equivalent), and ask to see it. A meaningful test script verifies specific negative cases, not just that an admin can grant access: that a read-only user's edit attempt is actually rejected and logged, that a revoked user's session is actually terminated, that a role change takes effect immediately rather than at next login. Just as important, that evidence should be refreshed with every software release, not produced once at initial deployment and never revisited — a permission model that passed validation two years ago tells you little about whether the current version still enforces it correctly.
A single clinical study routinely spans a sponsor's internal regulatory and clinical teams, one or more CROs, individual investigator sites, and periodic outside auditors or inspectors — often across several countries at once. Each group has a legitimately different relationship to the same TMF:
Without role-based controls, sponsors typically default to one of two flawed patterns: over-sharing (everyone gets broad access because it's easier to configure) or manual gatekeeping (a coordinator emails documents on request, which is slow and leaves no systematic access record). A validated, role-based eTMF is what makes controlled multi-stakeholder access — letting each party see exactly what their role requires, and nothing more — practical at the pace a live trial actually runs at.
Most organizations manage TMF access one of three ways. None of these is being ranked here — the right fit depends on team size, study complexity, and how many external parties need regular access; each approach has real tradeoffs worth weighing against your own situation.
| Approach | How access is controlled | Typical tradeoff |
|---|---|---|
| Shared drives + manual tracking | Folder-level permissions on a generic file share, often supplemented by a spreadsheet tracking who has access to what | Cheap to start, but permission changes are manual, easy to forget, and produce no reliable audit trail of who accessed what and when |
| Bolt-on permission or identity tool over a generic DMS | A separate access-management layer added on top of a document system not originally built for GxP access control | Can achieve granular roles, but the access-control layer and the document/audit-trail system are validated separately — and can drift out of sync after updates to either |
| Native role-based access in a validated eTMF platform | Roles, permissions, and the audit trail are built on the same underlying system and validated together | Access control and document history stay inherently consistent, at the cost of being tied to that platform's own role model rather than a fully custom one |
When comparing eTMF vendors specifically on access control, a few concrete questions tend to separate genuinely validated role-based access from a feature that exists mostly in the marketing copy:
Kivo's eTMF is built on the same Part 11-compliant document core as the rest of the platform, so role-based access control isn't a bolted-on layer — it's the same permission model, audit trail, and validation evidence across DMS, eTMF, RIM, and QMS. Every subscription includes role-based, per-user licensing across three license types — Full Platform, Limited/Read-Only Access, and 3rd-Party Access — so a CRO monitor, an investigator site, or an inspector can be scoped to exactly the access their role needs, including view-only access to final documents without exposure to drafts in progress. Granular, role-based permissions extend across every controlled document in the system, with an automatic, uneditable audit trail tied to each user's own login — no shared credentials.
Kivo's Inspection Readiness capability, part of its eTMF module, lets inspector-specific access be granted in minutes, scoped to final, non-draft documents only — directly addressing the fast-provisioning need described above. The platform also supports Single Sign-On, and Kivo's Trust Center documents a Least Privilege security principle across the platform, backed by SOC 2 Type 2 certification, AES-256 encryption at rest, and TLS 1.2 in transit. Because access control is part of the same system Kivo continuously validates under its CSA-aligned approach, customers review and approve that validation evidence rather than testing the access-control feature themselves.
User-based permissions are configured individually for each person, which becomes difficult to maintain consistently as a team or study roster grows. Role-based permissions assign access through a defined role — CRO monitor, site coordinator, auditor — so every person in that role gets the same, predictable level of access, and updating the role updates everyone assigned to it.
Kivo scopes access by role and license type — Full Platform, Limited/Read-Only, or 3rd-Party — so sponsors, CROs, and investigator sites each see only what their role requires, with every access event captured in an automatic, uneditable audit trail tied to the individual user's login.
Yes, in a well-designed system. Inspector- or auditor-specific access should be grantable in minutes, scoped only to final, approved documents rather than drafts still in progress, and fully revocable the moment the engagement ends — without ever requiring a full standing user account or a shared login.
Look for a platform that's pre-validated out of the box (so your team isn't performing its own software validation), supports weeks-not-months onboarding, and doesn't require dedicated IT or QA staff to configure role-based access and other Part 11 controls.
The regulatory requirements are the same regardless of company size, but a start-up team typically needs a system that's configurable without a large IT or validation staff — pre-validated, role-based access and audit trails out of the box rather than custom-built.